Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Melanoma 137Carcinoma, Non-Small-Cell Lung 38Carcinoma, Renal Cell 33Neoplasm Metastasis 32Prostatic Neoplasms 22Brain Neoplasms 21Lung Neoplasms 20Pancreatic Neoplasms 19Uveal Melanoma 17Neoplasms 17Carcinoma, Hepatocellular 13Breast Neoplasms 13Sarcoma 12Skin Neoplasms 10Kidney Neoplasms 10Urinary Bladder Neoplasms 9Squamous Cell Carcinoma of Head and Neck 9Glioblastoma 9Triple Negative Breast Neoplasms 8Ovarian Neoplasms 8Colorectal Neoplasms 8Carcinoma, Transitional Cell 8Small Cell Lung Carcinoma 7Multiple Myeloma 7Colonic Neoplasms 7Clear-cell metastatic renal cell carcinoma 7Recurrence 6Myelodysplastic Syndromes 6Diabetes Mellitus, Insulin-Dependent, 12 6Uterine Cervical Neoplasms 5

Interventions

Cyclophosphamide 12Etoposide 11Granulocyte Colony-Stimulating Factor 7Filgrastim 7Carboplatin 7etoposide phosphate 6Vincristine 5Methotrexate 5Cisplatin 5fludarabine 4Topotecan 4Thiotepa 4Stem Cell Transplantation 4Radiotherapy 4Mesna 4Melphalan 4Temozolomide 3Sirolimus 3Ifosfamide 3Busulfan 3Automobiles 3selinexor 2sargramostim 2fludarabine phosphate 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Leucovorin 2Ipilimumab 2Hydrocortisone 2Gemcitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Rhabdoid Tumor × Ipilimumab × Clear all
NCT05407441 2026-04-13

Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

Dana-Farber Cancer Institute

Phase 1/2 Active not recruiting
49 enrolled
Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

NCT04416568 2025-12-17

Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
45 enrolled
Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡